Obermatt
See Similar Stocks →

Flags

Financial distress

Evolus

NMQ:EOLS · US30052C1071
PharmaceuticalsSmall

360

40
Profit price83
Owner Earnings Yield1
Dividend Yield1
Price/Sales100
EV / Gross Profit59
Price/Book93
Return on Capital27
Cash Return on Capital14
EBIT Margin20
Gross Profitability100
Accruals50
Owner Earnings Margin36
Sales growth70
Profit growth91
Reinvestment24
Price momentum16
Debt load3
Refinancing91
Debt Payback1
Liquidity85
Analyst ratings41
Opinion Changes50
Price Target Upside79
Market mood85
Value Creation6/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Evolus doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA
IndustryPharmaceuticals
SizeSmall
TypePublic Company
ExchangeNASDAQGM
Founded2012
Employees368
Websiteevolus.com
ISINUS30052C1071
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
NutraceuticalLifestyleDermatologyBiotechnologyHealth CarePharmaceutical

Description

Evolus, Inc. operates as a global performance beauty company delivering breakthrough products with a customer-centric approach in the cash-pay aesthetic market. The company’s current commercial product portfolio includes Jeuveau (prabotulinumtoxinA-…

Analysis

Middle-of-the-road

Evolus, Inc. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

Valuation data is not available for this company.

The trajectory is moderate and the balance sheet is stretched. The company scores 6/20 on our value-creation score: not creating value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
95
2023202420252026

All-time high

95

Jun 2026

All-time low

33

Jan 2025

Average rank

66

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
100
41
40
62
Price/Earnings
100
4
100
16
Price/Book
93
1
100
28
Dividend Yield
1
1
1
1
Value (overall)
98
4
65
43

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Evolus with its peers
Anika Therapeutics
NSQ:ANIK
63
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Protagonist Therapeutics
NMQ:PTGX
27
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Invivyd
NMQ:IVVD
40
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Stoke Therapeutics
NSQ:STOK
16
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Atea Pharmaceuticals
NSQ:AVIR
5
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Precision BioSciences
NAQ:DTIL
39
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →